C. Sloss

发表

MAP Kinase Phosphatase-2 Plays a Critical Role in Response to Infection by Leishmania mexicana

C. Bryant, R. Plevin, J. Alexander, 2010, PLoS pathogens.

Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.

Sam W. Lee, J. Cusack, F. Wang, 2007, Cancer research.

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

A. Romanelli, S. Hicks, Y. Yi, 2017, Neoplasia.

Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase.

R. Plevin, P. Cameron, L. Cadalbert, 2005, Cellular signalling.

IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML

J. Pinkas, G. Schuurhuis, G. Ossenkoppele, 2018, Molecular Cancer Therapeutics.

Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells

Fang Wang, J. Cusack, M. Palladino, 2008, Clinical Cancer Research.

The role of intracellular Ca2+ in the regulation of proteinase‐activated receptor‐2 mediated nuclear factor kappa B signalling in keratinocytes

R. Plevin, T. Kanke, P. Cameron, 2005, British journal of pharmacology.

Signaling Pathways in Pancreatic Cancer Cells Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Proteasome Inhibition Activates Epidermal Growth Factor

Liu, Michael, M. Palladino, 2008 .

G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes.

R. Plevin, M. Nilsson, M. Cunningham, 2008, Cellular signalling.

Inactivation of JNK activity by mitogen-activated protein kinase phosphatase-2 in EAhy926 endothelial cells is dependent upon agonist-specific JNK translocation to the nucleus.

R. Plevin, C. Sloss, C. Robinson, 2001, Cellular signalling.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

P. Richardson, Y. Oki, H. Ovaa, 2011, Current cancer drug targets.

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

K. Flaherty, J. Wargo, D. Fisher, 2010, Cancer research.

Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2.

R. Plevin, J. Shipley, M. Cunningham, 2010, Cellular signalling.

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

U. Nielsen, J. Fitzgerald, O. Burenkova, 2015, Molecular Cancer Therapeutics.

Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance

J. Cusack, S. W. Lee, F. Wang, 2007, Oncogene.

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2019, Blood.

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

M. Konopleva, A. Romanelli, Qi Zhang, 2019, Blood.

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

M. Konopleva, G. Gaidano, H. Kantarjian, 2021, Blood.

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

P. Vyas, M. Konopleva, G. Gaidano, 2022, Blood.

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2021, Blood.

PF201 THE COMBINATION OF IMGN632, A CD123-TARGETING ADC, WITH VENETOCLAX ENHANCES ANTI-LEUKEMIC ACTIVITY IN VITRO AND PROLONGS SURVIVAL IN VIVO IN PRE-CLINICAL MODELS OF HUMAN AML

M. Konopleva, A. Romanelli, Qi Zhang, 2019, HemaSphere.

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

E. Wang, Sharlene Adams, C. Fritz, 2018, Blood.

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

J. Cortes, D. DeAngelo, E. Traer, 2018, Blood.

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

M. Konopleva, H. Kantarjian, N. Daver, 2018, Blood.

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

L. Cascione, D. Rossi, A. Stathis, 2019, Haematologica.

A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.

N. Daver, D. DeAngelo, E. Wang, 2020 .

Disruption of two putative nuclear localization sequences is required for cytosolic localization of mitogen-activated protein kinase phosphatase-2.

S. G. Finn, S. Fuller, R. Plevin, 2005, Cellular signalling.

A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.

M. Konopleva, A. Lane, G. Martinelli, 2020 .

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2020 .

Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.

M. Beeram, A. Adjei, B. Wolf, 2015 .

Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells

J. Cusack, F. Wang, M. Palladino, 2010, Oncogene.

IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

A. Romanelli, Nemisha Dawra, Jennifer A. Coccia, 2015 .

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

K. Flaherty, J. Wargo, D. Fisher, 2010, Cancer research.

Strathprints Institutional Repository Map Kinase Phosphatase-2 Plays a Critical Role in Response to Infection by Leishmania Mexicana

R. Plevin, J. Alexander, Muhannad Shweash, 2022 .

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

L. Cascione, A. Stathis, M. Davids, 2023, bioRxiv.

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

L. Cascione, D. Rossi, A. Stathis, 2016 .